| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
31.03.2025 08:27:26
|
AstraZeneca's Imfinzi Combo Approved In US For Muscle-Invasive Bladder Cancer Treatment
(RTTNews) - British drug major AstraZeneca Plc.'s (AZN, AZN.L) Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).
The approval was granted by the Food and Drug Administration (FDA) after securing Priority Review and was based on results from the NIAGARA Phase III trial. The results showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death compared to neoadjuvant chemotherapy alone.
Imfinzi is also approved in Brazil in the setting based on the NIAGARA results. Regulatory applications are currently under review in the EU, Japan and several other countries.
For More Such Health News, visit rttnews.com.
Nachrichten zu AstraZeneca PLC (spons. ADRs)
|
01.05.25 |
NASDAQ 100-Handel aktuell: NASDAQ 100 mittags stärker (finanzen.ch) | |
|
01.05.25 |
Freundlicher Handel in New York: NASDAQ 100 verbucht zum Start des Donnerstagshandels Zuschläge (finanzen.ch) | |
|
30.04.25 |
Zurückhaltung in New York: NASDAQ 100 zum Handelsstart leichter (finanzen.ch) | |
|
29.04.25 |
AstraZeneca-Aktie verlustreich: AstraZeneca bleibt auch zum Jahresstart auf Wachstumskurs (finanzen.ch) | |
|
29.04.25 |
Astrazeneca droht Millionenstrafe in China - Aktie verliert nach Zahlen (AWP) | |
|
28.04.25 |
NASDAQ-Handel NASDAQ 100 präsentiert sich mittags schwächer (finanzen.ch) | |
|
28.04.25 |
Ausblick: AstraZeneca stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
|
21.04.25 |
Schwache Performance in New York: NASDAQ 100-Börsianer bekommen mittags kalte Füsse (finanzen.ch) |